Orforglipron
FDA status: FDA has approved products that contain orforglipron, including Foundayo.
PubMed: 145 publications mention Orforglipron, 46 of them trials or reviews. Search PubMed
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Wharton S et al. The New England journal of medicine, 2025. Randomized Controlled Trial, Clinical Trial, Phase III. PMID 40960239 · DOI
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Rosenstock J et al. Lancet (London, England), 2026. Clinical Trial, Phase III, Randomized Controlled Trial. PMID 41765029 · DOI
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. Rosenstock J et al. The New England journal of medicine, 2025. Randomized Controlled Trial, Clinical Trial, Phase III. PMID 40544435 · DOI
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. Nong K et al. BMJ (Clinical research ed.), 2026. Systematic Review, Network Meta-Analysis. PMID 42419792 · DOI
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Pratt E et al. Diabetes, obesity & metabolism, 2023. Randomized Controlled Trial, Clinical Trial, Phase I. PMID 37344954 · DOI
ClinicalTrials.gov: 53 registered studies. See all studies
- NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (Phase 3), completed
- NCT07241390 A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) (Phase 3), recruiting
MedlinePlus drug information ↗FDA label (DailyMed) ↗RxNorm 2739838 ↗PubChem CID 137319706 ↗Wikipedia ↗





